Filing Flows › Novo Nordisk A S (NVO) › Q2 2026
Novo Nordisk A S (NVO) Q2 2026 earnings results (second quarter 2026)
6-K filed Aug 4, 2026
Novo Nordisk A S (NVO) reported revenue of $78.5B for the second quarter 2026 (Q2 2026). Operating margin was 34.5%, net earnings $21.0B (26.7% of revenue).
Novo Nordisk A S, Q2 2026: revenue $78.5B, operating margin 34.5%, net earnings $21.0B, operating cash flow $55.2B. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $78.5B | — | — |
| Gross profit | $61.4B | — | — |
| Operating profit | $27.1B | — | — |
| Net earnings | $21.0B | — | — |
| Operating cash flow | $55.2B | — | — |
| Free cash flow | $42.5B | — | — |
What changed
Revenue was DKK 78.5B in Q2 2026. Obesity and Diabetes care was the largest line at 94% of revenue.
Gross margin was 78.2%. Operating profit was DKK 27.1B, a 34.5% margin. Net earnings were DKK 21.0B. The effective tax rate was 21.9%.
Operating cash flow was DKK 55.2B, 263% of net earnings. Working capital and other items added DKK 34.2B. Capital expenditures of DKK 12.7B left free cash flow of DKK 42.5B.
Questions
What was Novo Nordisk A S' revenue in the second quarter 2026?
Novo Nordisk A S (NVO) reported revenue of $78.5B for the second quarter 2026 (Q2 2026).
Was Novo Nordisk A S profitable in the second quarter 2026?
Operating profit was $27.1B (34.5% of revenue) and net earnings $21.0B.
Source: Novo Nordisk A S 6-K on SEC EDGAR.